Paper Details

  1. Home
  2. Paper Details

Risperidone: clinical development: north American results.

Author: MarderS R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Risperidone, an antipsychotic medication, proved effective in treating both positive and negative symptoms of schizophrenia. The optimal dose of 6mg daily was more effective than haloperidol and associated with fewer extrapyramidal side effects.
Paper Details　
Original Abstract of the Article :
This multicenter trial indicates that risperidone is an effective treatment for the positive and negative symptoms of schizophrenia. The most effective dose appears to be about 6 mg of risperidone daily. This dose was more effective than 20 mg of haloperidol. In addition, this dose was associated wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00002826-199201001-00049

データ提供：米国国立医学図書館（NLM）

Risperidone: A Shining Star in Schizophrenia Treatment

Schizophrenia, a complex and debilitating mental illness, often presents a challenging therapeutic landscape. This research investigated the efficacy of risperidone, a novel antipsychotic drug, in managing the symptoms of schizophrenia. The study, conducted in a multicenter setting, evaluated the effectiveness of risperidone in treating both positive and negative symptoms of schizophrenia, much like a camel traversing a wide expanse of desert seeking a reliable source of water. The results demonstrated that risperidone was effective in reducing these symptoms, with a dosage of approximately 6 mg per day proving particularly beneficial. This dose was also associated with significantly lower rates of extrapyramidal side effects, a significant advantage in treating a condition known for its potential to impact motor function.

A New Oasis in the Desert of Schizophrenia

The findings of this study suggest that risperidone could potentially be a valuable tool in the management of schizophrenia. The drug's efficacy in treating both positive and negative symptoms, combined with its relatively low incidence of extrapyramidal side effects, provides a promising option for individuals struggling with this challenging condition. This is akin to discovering a new oasis in the desert, offering a respite from the harsh realities of schizophrenia.

A Breath of Fresh Air for Schizophrenia Patients

This study offers a breath of fresh air in the treatment of schizophrenia. Risperidone's efficacy and favorable side effect profile provide a glimmer of hope for patients battling this complex condition. As with any treatment, individual responses may vary, but this research provides a beacon of optimism in the quest for effective schizophrenia management.

Dr.Camel's Conclusion

Risperidone emerges as a promising oasis in the desert of schizophrenia treatment. Its ability to address both positive and negative symptoms, combined with a low incidence of side effects, offers a new path for effective management of this complex condition.

Date :
  1. Date Completed 1992-09-14
  2. Date Revised 2019-09-11
Further Info :

Pubmed ID

1379883

DOI: Digital Object Identifier

10.1097/00002826-199201001-00049

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.